response from WP - re 4C, page-80

Good point - US probably 50% of sales at least so more like $100k, but wouldn't be game changing either way. We need a step change to $3M+ next quarterly. Hurricane or not.

Interesting to look at the Adapt update from the AR:

Europe is a dead weight at the moment, lots of costs and mediocre growth. The growth out of emerging markets is promising if the current levels can be sustained. They do not seem to mention the $ value for MENA / Asian sales. Does anyone know if market by market revenue information has been shared? Would like to see where Asia is up to, because 55% quickly adds up if the base is not tiny.

Does anyone know what the TGA approval "positive flowon
effects" refers to? Does Philippines, Thailand, Taiwan and Vietnam accept TGA approvals? Surely if that was the case then FDA and CE Mark would be enough??

Growth figures from the annual report:
North American sales up 35% (40% in
constant currency) on the prior year. Europe grew
modestly, up 9% (15% in constant currency) due to
a refocus on core markets following the Company’s
strategic review. Emerging Markets were up 170%,
albeit from a low base, driven primarily by sales to the
MENA region following granting of sales approval to
United Arab Emirates. Sales in its other open markets
such as Singapore, Hong Kong and Malaysia grew
strongly, up 55% on the prior year. The hoped-for
TGA approval in Australia – which has positive flowon
effects to a number of markets in Asia, including
Philippines, Thailand, Taiwan and Vietnam – is now
anticipated mid-2018.